. Author manuscript; available in PMC: 2021 Dec 1.

Published in final edited form as: Semin Arthritis Rheum. 2020 Mar 19;50(6):1542–1548. doi: 10.1016/j.semarthrit.2020.03.003

Table 4.

Sensitivity analyses showing different testing windows for HBV, HCV, and TB for new users of biologic therapies, N (%)

	HBV	HCV	TB	Composite measure
Primary analysis^*	7,731 (28.8)	10,854 (40.5)	7,117 (29.7)	4,157 (15.5)
Sensitivity analysis 1^†	8,794 (32.8)	12,110 (45.2)	9,813 (40.9)	4,919 (18.4)
Sensitivity analysis 2^**	9,143 (34.1)	12,527 (46.7)	15,231 (63.4)	6,675 (24.9)

Primary analysis: HBV (Hepatitis B virus) and HCV (Hepatitis C virus) testing were required to have occurred at any time prior to the index date; TB (tuberculosis) testing was required in the 12 months prior to the index date.

^†

Sensitivity analysis 1: for HBV and HCV, this window was defined as any time prior to the index date through 60 days after the index date; for TB testing, this window was defined as 12 months prior to the index date through 60 days after the index date.

^**

Sensitivity analysis 2: for all tests we searched all available data, including both before and after the index date.